Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare Conference
July 24, 2018 08:30 ET
|
Verona Pharma plc
LONDON, July 24, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma to Present at Upcoming Investor Conferences
May 30, 2018 08:30 ET
|
Verona Pharma plc
LONDON, May 30, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma Files Shelf Registration Statement with SEC
May 23, 2018 02:00 ET
|
Verona Pharma plc
LONDON, May 23, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD
May 21, 2018 17:15 ET
|
Verona Pharma plc
LONDON, May 21, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and...
Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
May 08, 2018 02:00 ET
|
Verona Pharma plc
Announced positive top-line data from two Phase 2 clinical trials ahead of schedule Met primary and key secondary endpoints in 403 patient Phase 2b clinical trial for maintenance treatment of COPD ...
Verona Pharma Announces Departure of Chief Medical Officer
April 11, 2018 02:00 ET
|
Verona Pharma plc
LONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and...
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD
March 26, 2018 02:00 ET
|
Verona Pharma plc
Primary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels Clinically relevant secondary endpoints were also met, including...